Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy (CYCLUS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by University Hospital, Linkoeping.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Swedish Lung Cancer Study Group
Pfizer
Information provided by:
University Hospital, Linkoeping
ClinicalTrials.gov Identifier:
NCT00300729
First received: March 8, 2006
Last updated: June 29, 2009
Last verified: June 2009

March 8, 2006
June 29, 2009
May 2006
May 2010   (final data collection date for primary outcome measure)
Overall survival [ Time Frame: Minimum follow-up 1 yr after randomization ] [ Designated as safety issue: No ]
Overall survival
Complete list of historical versions of study NCT00300729 on ClinicalTrials.gov Archive Site
  • Quality of life [ Time Frame: Week 0, 3, 6, 9, 12, 20, 28, 36, 44 ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: minimum follow-up 1 yr after randomization ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: Within one month after stopping study drug ] [ Designated as safety issue: Yes ]
  • Cardiovascular events [ Time Frame: Within one month after stopping study drug ] [ Designated as safety issue: Yes ]
  • Biological parameters (plasma VEGF, proteomics) [ Time Frame: Week 0, 6, 12, and 20 ] [ Designated as safety issue: No ]
  • Quality of life
  • Progression-free survival
  • Toxicity
  • Cardiovascular events
  • Biological parameters (plasma VEGF, proteomics)
Not Provided
Not Provided
 
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study

The primary purpose of the study is to investigate if daily treatment with celecoxib, an inhibitor of cyclooxygenase-2, can prolong survival in patients with advanced non-small cell lung cancer who receive anticancer chemotherapy as their primary treatment. Secondary endpoints of the study are: health-related quality of life, toxicity, cardiovascular events, progression-free survival, and biological markers (VEGF, proteomics).

The study (CYCLUS trial, CY-cyclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival) is a prospective randomized double-blind multicenter trial. Patients are randomized to receive celecoxib at a dose of 400 mg b.i.d. or placebo. Primary endpoint of the trial is survival. Secondary endpoints are: quality of life, progression-free survival, toxicity, cardiovascular events, and biological parameters (plasma VEGF and proteomics).

The rationale behind the study consists of preclinical observations of antitumor effect of celecoxib in NSCLC. Inhibition of angiogenesis and proliferation as well as increased apoptosis has been demonstrated. In addition, pilot studies have shown that the combination of chemotherapy and celecoxib is feasible. No unexpected toxicity has been recorded in such trials. Furthermore, a randomized study of indomethacin, prednisolone or placebo in other types of advanced cancer, mainly gastrointestinal, showed a survival advantage for patients receiving antiinflammatory treatment.

Chemotherapy is given according to the current standard of the participating institution. In practice, patients will usually receive either carboplatin + gemcitabine or carboplatin + vinorelbine. Treatment duration with chemotherapy is 4 cycles (cycle length 3 weeks) in the absence of tumour progression or prohibitive toxicity.

Treatment with the study drug starts on the first day of cancer chemotherapy. Maximum treatment duration is one year. Treatment will be stopped earlier in case of objective tumor progression, serious toxicity that is considered to be related to the study drug or if the patient wants to stop treatment.

The size of the study is based on the hypothesis that celecoxib could prolong median survival by 8 weeks as compared to 7.5 months in the placebo group. With standard statistical requirements (type I error 5%, type II error 20%), the calculated number of patients was 760.

The study was supported by the Swedish Lung Cancer Study Group and organized as a multicenter trial, with participation of seven university hospitals and six smaller hospitals. The number of new cases of NSCLC stage IIIB-IV and performance status 0-2 in Sweden is around 1200/year. It was expected that 20% of the patients could be included in the study, which would make completion possible in three years.

The study was opened for randomization on May 31, 2006. Recruitment of patients was lower than expected. The study was closed for further randomization on May 31, 2009, as originally planned. 319 patients were included. Since maximum duration of treatment with the study drug is one year, the code will be broken after May 31, 2010. Data analysis is planned to take place in summer and autumn, 2010.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Non-Small Cell Lung Cancer
  • Drug: Celecoxib
    Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
    Other Names:
    • Celebra
    • Onsenal
  • Drug: Placebo
    One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
  • Active Comparator: Celecoxib
    Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
    Intervention: Drug: Celecoxib
  • Placebo Comparator: Placebo
    Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
    Intervention: Drug: Placebo
Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sörenson S; Swedish Lung Cancer Study Group. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035. Epub 2011 May 10.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
319
September 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  • Age at least 18 years. No upper age limit.
  • Disease stage IIIB or IV.
  • Performance status (WHO) 0-2
  • Treatment with curative intent is not possible
  • No prior chemotherapy for the present disease
  • Planned treatment is palliative chemotherapy
  • WBC count at least 3.0, platelet count at least 100
  • Bilirubin < 1.5 * upper reference limit (URL), ASAT and ALAT < 3 * URL (<5 in case of liver metastases)
  • Calculated creatinine clearance at least 40 mg/ml
  • Informed oral and written consent

Exclusion criteria:

  • Regular use of NSAID (except ASA at a dose of 50-100 mg daily)
  • Active duodenal ulcer, ongoing gastrointestinal bleeding or inflammatory bowel disease
  • Serious heart failure or serious liver disease
  • Hypersensitivity so sulfonamides
  • Pregnancy
  • Lactation
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00300729
SLCSG0501
Yes
Sverre Sörenson, MD, PhD, Swedish Lung Cancer Study Group
University Hospital, Linkoeping
  • Swedish Lung Cancer Study Group
  • Pfizer
Study Chair: Sverre Sörenson, MD, PhD Department of Medicine, Ryhov County Hospital, Jönköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
Principal Investigator: Andrea Koch, MD Allergy Centre, University Hospital, Linköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
University Hospital, Linkoeping
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP